SARS-CoV-2 in multiple myeloma: initial observation and management (2020)

Click to increase image sizeClick to decrease image size AcknowledgmentsWe would like to thank participating patients and their families.Author contributionsElisabet E. Manasanch designed the research, collected and analyzed data and wrote the manuscript. Victor Mulanovich contributed patients and provided manuscript comments. Joanna Grace Manzano contributed patients and provided manuscript comments. Maria Susan Gaeta contributed patients and gave manuscript comments. M. Becnel contributed patients and gave manuscript comments. Gregory Kaufman contributed patients and gave manuscript comments. Hans Lee contributed patients and gave manuscript comments. S. Thomas contributed patients and gave manuscript comments. Behrang Amini contributed patients and gave manuscript comments. Swaminathan P Iyer contributed patients and gave manuscript comments. Donna M. Weber contributed patients and provided manuscript comments. Zuzana Berkova analyzed data and provided manuscript comments. C. R. Flowers provided manuscript comments. Robert Z. Orlowski designed the research, contributed patients and wrote the manuscript. Krina Patel designed the research, collected and analyzed data and wrote the manuscript.Disclosure statementE. E. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, Sanofi, Janssen, GSK and Adaptive Biotechnologies.V. Mulanovich reports no conflicts of interest. J. G. Manzano reports no conflicts of interest.M. S. Gaeta reports no conflicts of interest. M. Becnel reports no conflicts of interest. G. Kaufman reports no conflicts of interest.H. Lee has received consulting fees from Adaptive Biotechnologies, Amgen, Celgene, GlaxoSmithKline, Janssen, Sanofi, and Takeda and research support from Amgen, Daiichi Sankyo, GlaxoSmithKline, Janssen, and Takeda.S. Thomas reports no conflicts of interest. B. Amini reports no conflicts of interest. S. P. Iyer reports no conflicts of interest. D. M. Weber reports no conflicts of interest.C. R. Flowers declares being a consultant in the past 3 years for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum. Research Funding in the past 12 months: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation.R. Orlowski declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and is a Founder of Asylia Therapeutics, Inc., with an equity interest.K. Patel has received consulting fees from Celgene, BMS, Janssen, Takeda, Pfizer, Precision Biosciences, Oncopeptides, Nektar andd research support from Celgene, BMS, Janssen, Poseida, Cellectis, Takeda, Abbvie, Precision Biosciences, and Nektar.Additional informationFundingThis work was also supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society (SCOR-12206-17), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, The Chapman Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia & Lymphoma Society (SCOR-12206-17), the Brock Family Myeloma Research Fund, and the Jean Clarke High-Risk Myeloma Research Fund.